Eli Lilly and Company (LLY BE) stock market data APIs
€705.2841
0(0%)
as of October 16, 2025
Try our APIs with
free plan!
Eli Lilly and Company Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for LLY.BE.
Prev. Close
705.2841
Open
705.2841
High
705.2841
Low
705.2841
52 wk Range
538.3723-878.5214
Market Cap
206 794 M
EPS
3.34
Dividends (Yield)
0.0146
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eli Lilly and Company data using free add-ons & libraries
Get Eli Lilly and Company Fundamental Data
Eli Lilly and Company Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-01
- EPS/Forecast: 3.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eli Lilly and Company News
New
Johnson & Johnson’s (JNJ) Stock Is Now Positioned To “Challenge Eli Lilly,” Says Jim Cramer
We recently published Jim Cramer Talked About These 8 Stocks & The Quantum Computing Dip. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ)...
A Look at Eli Lilly’s Valuation Following Landmark Orforglipron Phase 3 Results
Eli Lilly (LLY) just reported that its investigational pill, orforglipron, achieved every main and secondary goal in two late-stage clinical trials for type 2 diabetes. The data showed better blood su...
LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
Eli Lilly LLY announced positive top-line data from two late-stage studies evaluating orforglipron, its once-daily oral GLP-1 pill, in patients with type II diabetes (T2D). The ACHIEVE-2 study compar...
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Novo Nordisk NVO and Omeros Corporation OMER have announced the signing of a definitive asset purchase and license agreement for zaltenibart (formerly OMS906), a clinical-stage candidate targeting rar...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
